• Molecular NameTrimetrexate
  • SynonymTMQ; TMX; Trimetrexato [INN-Spanish]; Trimetrexatum [INN-Latin]
  • Weight370.413
  • Drugbank_IDDB01157
  • ACS_NO52128-35-5
  • Show 3D model
  • LogP (experiment)2.55
  • LogP (predicted, AB/LogP v2.0)1.96
  • pkaN/A
  • LogD (pH=7, predicted)1.53
  • Solubility (experiment)N/A
  • LogS (predicted, ACD/Labs)(ph=7)-4.32
  • LogSw (predicted, AB/LogsW2.0)0.05
  • Sw (mg/ml) (predicted, ACD/Labs)0.01
  • No.of HBond Donors5
  • No.of HBond Acceptors9
  • No.of Rotatable Bonds6
  • TPSA130.43
  • StatusFDA approved
  • AdministrationN/A
  • PharmacologyA quinazoline derivative. It is a dihydrofolate reductase inhibitor.
  • Absorption_valueN/A
  • Absorption (description)N/A
  • Caco_2N/A
  • Bioavailability45.0
  • Protein binding97.0
  • Volume of distribution (VD)Plasma, 0.17 L/kg; steady state, 0.62 L/kg (20 L/m2); steady state in AIDS patients, 11 to 20 L/m2; in cancer patients, 12 to 42 L/m2.
  • Blood/Plasma Partitioning ratio (D_blood)N/A
  • MetabollsmOxidative O-demethylation, followed by conjugation with glucuronide or sulfate
  • Half life11~16.4 h
  • ExcretionN/A
  • Urinary ExcretionN/A
  • CleranceN/A
  • ToxicityThe LD50 of intravenous trimetrexate in mice is 62 mg/kg (186 mg/m2). Myelosuppression is a dose-limiting toxic effect.
  • LD50 (rat)N/A
  • LD50 (mouse)N/A